within Pharmacolibrary.Drugs.ATC.A;

model A07FA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07FA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Saccharomyces boulardii is a probiotic yeast used in the prevention and treatment of gastrointestinal disorders such as antibiotic-associated diarrhea, travelers’ diarrhea, and some forms of infectious diarrhea. It is not a pharmacological drug but a living microorganism that acts by modulating the gut flora and local immunity. It is approved and widely used as an over-the-counter probiotic supplement in many countries.</p><h4>Pharmacokinetics</h4><p>No classical pharmacokinetic parameters are reported because Saccharomyces boulardii is a living microorganism, not absorbed systemically, and exerts its effects locally in the gastrointestinal tract in both adult and pediatric populations.</p><h4>References</h4><ol><li><p>Selig, DJ, et al., &amp; Livezey, JR (2020). Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin. <i>Drug metabolism and personalized therapy</i> 35(1) –. DOI:<a href=&quot;https://doi.org/10.1515/dmpt-2019-0032&quot;>10.1515/dmpt-2019-0032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32134728/&quot;>https://pubmed.ncbi.nlm.nih.gov/32134728</a></p></li><li><p>Li, M, et al., &amp; Yuan, J (2015). Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. <i>Inflammation</i> 38(1) 170–179. DOI:<a href=&quot;https://doi.org/10.1007/s10753-014-0019-7&quot;>10.1007/s10753-014-0019-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25227279/&quot;>https://pubmed.ncbi.nlm.nih.gov/25227279</a></p></li><li><p>Justino, PF, et al., &amp; Soares, PM (2014). Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. <i>The British journal of nutrition</i> 111(9) 1611–1621. DOI:<a href=&quot;https://doi.org/10.1017/S0007114513004248&quot;>10.1017/S0007114513004248</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24503021/&quot;>https://pubmed.ncbi.nlm.nih.gov/24503021</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07FA02;
